

Date: 14 November 2025

To,

Corporate Relationship Department, BSE Limited PJ Towers, Dalal Street, Mumbai 400001, MH

Stock Code: 542248

Subject: Investors' Presentation on Financial Results for the Quarter ended 30 September 2025

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Investors' Presentation on Financial Results for the quarter ended 30 September 2025.

The above information is being hosted on the Company's website <a href="www.deccanhealthcare.co.in">www.deccanhealthcare.co.in</a> in terms of Regulation 46 of the Listing Regulations, as amended

You are requested to take the same on record.

Thanking You,
For and on behalf of
Deccan Health Care Limited

Ronak Darji Company Secretary & Compliance Officer

Encl: A/a

Registered Office: 6-3-347/17/5/A/Back Position, Dwarakapuri Colony, Punjagutta, Hyderabad – 500082, Telangana, India Email: info@deccanhealthcare.co.in

Tel: +91 40 4709 6427

Innovation Hub & Manufacturing: Plot No.13, Sector 03, IIE Pant Nagar, SIDCUL, Udham Singh Nagar – 263153, Uttarakhand, India CIN: L72200TG1996PLC024351

www.deccanhealthcare.co.in



### Financial Highlights 2025–26 (Q2)







#### Revenue

- Standalone:
  - Quarter Performance: ₹2,440.46 lakh (Growth: +29.7% YoY)
  - Half-Yearly Performance: ₹4,587.41 lakh (Growth: +35.4% YoY) ↑
- Consolidated:
  - Quarter Performance: ₹2,139.56 lakh
  - Half-Yearly Performance: ₹4,353.58 lakh

Revenue Trend – Robust YoY growth driven by product diversification, digital and retail expansion, and high consumer demand in preventive wellness.





- Standalone:
  - Quarterly PAT: ₹89.97 lakh (Up: 67.5% YoY)
  - Half-Yearly PAT: ₹111.22 lakh (Up: 22.8% YoY) ↑
- Consolidated:
  - Quarterly PAT: ₹91.40 lakh
  - Half-Yearly PAT: ₹115.11 lakh
- Expected to sustain and increase in H2



#### **EPS Trend**

- Increase to ₹0.36 vs ₹0.09 QoQ
- EPS steady and improving, signalling value accretion and expected to increase





- Q2 EBITDA: ₹171.08 lakh (+136% QoQ)
- Margin improved to 7.0% from 3.4%
- Strong scale efficiencies & cost discipline visible



### Compliance & Governance

- Zero investor complaints
- Timely MCA compliances
- Strong governance this reinforces the company's reputation for sound governance and responsible management.

### Strategic Growth Drivers



## Weight Wellness Program driving higher engagement

An integrated, science-backed approach to achieving and maintaining an ideal body weight with sustained energy, strength, and balance

# Stronger presence in functional foods (fruit bars, gummies)

With innovative fruit bars and gummies, Deccan Health Care continues to tap into the booming functional nutrition space, combining taste, health, and convenience.

## Continued focus on science-backed innovation

The company remains committed to developing clinically researched, sciencedriven formulations that enhance efficacy, safety, and consumer trust across its wellness portfolio.

### **Export Expansion Outlook**



### Regulatory approvals filed in 6 international markets

Completed filings to enable strategic international launches and strengthen global footprint.

## UAE & GCC launch targeted for March 2026

With product
launches in the UAE
and GCC scheduled
for March 2026,
reinforcing Deccan
Health Care's
strategic focus on
global growth and
market presence.

## Large addressable market in preventive wellness


Strong growth opportunity driven by rising health awareness and increasing demand for preventive nutrition.





- Strong YoY revenue & profit growth momentum
- Rising EBITDA & margin expansion
- Strong equity base
- High-growth nutraceutical sector
- Export-driven multi-year growth visibility
- Strong governance and compliances







Disclaimer: This communication, except for the historical information, may contain statements which reflect the Management's current views and estimates and could be construed as forward-looking statements. The future involves many risks and uncertainties that could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include such factors as general economic conditions, foreign exchange and commodity price fluctuations, competitive product and pricing pressures and regulatory developments.



